Gillette-Guyonnet, Sophie, Andrieu, Sandrine, Dantoine, Thierry, Dartigues, Jean-François, Touchon, Jacques, Vellas, B.

Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]

Bayer-Carter, Jennifer L., Green, Pattie S., Montine, Thomas J., VanFossen, Brian, Baker, Laura D., Watson, G. Stennis, Bonner, Laura M., Callaghan, Maureen, Leverenz, James B., Walter, Brooke K., Tsai, Elaine, Plymate, Stephen R., Postupna, Nadia, Wilkinson, Charles W., Zhang, Jing, Lampe, Johanna, Kahn, Steven E., Craft, Suzanne

Objective: To compare the effects of a 4-week high-saturated fat/high-glycemic index (HIGH) diet with a low-saturated fat/low-glycemic index (LOW) diet on insulin and lipid metabolism, cerebrospinal fluid (CSF) markers of Alzheimer disease, and cognition for healthy adults and adults with amnestic mild cognitive impairment (aMCI).; Design: Randomized controlled trial.; Setting: Veterans Affairs Medical Center clinical […]

Serrano-Pozo, Alberto, Vega, Gloria L., Lütjohann, Dieter, Locascio, Joseph J., Tennis, Marsha K., Deng, Amy, Atri, Alireza, Hyman, Bradley T., Irizarry, Michael C., Growdon, John H.

Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]

Wang, Tao, Huang, Qiu, Reiman, Eric M., Chen, Kewei, Li, Xia, Li, Guanjun, Lin, Zhiguang, Li, Chunbo, Xiao, Shifu

Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]

Liu, Yongzhe, Pan, Ningling, Ma, Yaqun, Zhang, Shengshuo, Guo, Wenzhi, Li, Haihong, Zhou, Jingli, Liu, Gang, Gao, Minglong

Background: Amnestic mild cognitive impairment (aMCI) is thought to be a transitional stage between normal aging and the development of Alzheimer’s disease (AD). Recent studies have suggested that the inhalational anesthetic isoflurane can induce caspase activation and apoptosis, increase aggregates of β-amyloid (Aβ) levels, and enhance Aβ aggregation. The aim of this study was to […]

Aboulafia-Brakha, T., Suchecki, D., Gouveia-Paulino, F., Nitrini, R., Ptak, R.

Background: Family caregivers of patients with dementia frequently experience psychological stress, depression and disturbed psychophysiological activity, with increased levels of diurnal cortisol secretion.; Objectives: To compare the effects of a cognitive-behavioural group therapy (CBT) to a psychoeducation group programme (EDUC) on cortisol secretion in caregivers of patients with moderate Alzheimer’s disease (AD).; Method: Caregivers of […]

Squitieri, Ferdinando, Orobello, Sara, Cannella, Milena, Martino, Tiziana, Romanelli, Pantaleo, Giovacchini, Giampiero, Frati, Luigi, Mansi, Luigi, Ciarmiello, Andrea

Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.; Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated […]

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., Mulnard, R., Barakos, J., Gregg, K. M., Liu, E., Lieberburg, I., Schenk, D., Black, R., Grundman, M.

Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]

Riby, L. M., Marriott, A., Bullock, R., Hancock, J., Smallwood, J., McLaughlin, J.

Background/objectives: Previous research investigating the impact of glucose ingestion and/or improvements in glucose regulation has found selective cognitive facilitation on episodic memory tasks in successful ageing and dementia. The present study aimed to extend this research to mild cognitive impairment (MCI).; Subjects/methods: In a repeated-measures design, 24 older adults with and 24 older adults without […]

Paraskevas, G. P., Kapaki, E., Papageorgiou, S. G., Kalfakis, N., Andreadou, E., Zalonis, I., Vassilopoulos, D.

Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 […]